Journal
PULMONARY CIRCULATION
Volume 12, Issue 4, Pages -Publisher
WILEY
DOI: 10.1002/pul2.12117
Keywords
pulmonary arterial hypertension; pulmonary fibrosis; scleroderma
Funding
- Forma Therapeutics
- Rheumatology Research Foundation
- Health Resources and Services Administration [U1EMC27864-0800]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [CCCR P30 AR072571]
- Novartis
- Arena/United Therapeutics
- Bayer
- National Center for Advancing Translational Sciences [2UL1TR00143005A1]
- Parker B. Francis Fellowship Award
- National Heart, Lung, and Blood Institute [1F32HL156614-01, 1UG3HL143192-01A1, 5F32HL149236-02]
Ask authors/readers for more resources
The study aimed to investigate the clinical features of patients with systemic sclerosis complicated by pulmonary hypertension (SSc-PH) and interstitial lung disease (SSc-PH-ILD), and analyze how the severity of ILD and PH contribute to the mortality rate in SSc patients. The results showed that severe ILD was associated with increased hazards for all-cause mortality in patients with SSc-PH, while mild and moderate ILD had no impact on mortality risk. In patients with SSc-ILD, both moderate and severe PH were associated with increased mortality risk, while mild PH had no impact. The findings suggest that early intervention may benefit disease progression.
Patients with systemic sclerosis complicated by both pulmonary hypertension (SSc-PH) and interstitial lung disease (SSc-PH-ILD) have poor prognosis compared to those with SSc-PH or SSc-ILD alone. Little is known of how ILD severity affects outcomes in those with SSc-PH, or how PH severity affects outcomes in those with SSc-ILD. Herein, we aimed to delineate clinical features of patients with SSc-PH and SSc-ILD and determine to what degree PH and ILD severity contribute to mortality in patients with SSc. We conducted parallel retrospective studies in cohorts of patients with SSc-PH and SSc-ILD. We categorized ILD severity by pulmonary function testing and PH severity by cardiopulmonary hemodynamics. Our primary outcome was all-cause mortality from time of PH or ILD diagnosis for the SSc-PH and SSc-ILD cohorts, respectively. We calculated adjusted risks of time to all-cause mortality using Cox proportional hazards models. In patients with SSc-PH, severe ILD (HR: 3.54; 95% CI: 1.05, 11.99) was associated with increased hazards for all-cause mortality. By contrast, mild and moderate ILD were not associated with increased mortality risk. In patients with SSc-ILD, both moderate (HR: 2.65; 95% CI: 1.12, 6.31) and severe PH (HR: 6.60; 95% CI: 2.98, 14.61) were associated with increased hazards for all-cause mortality, while mild PH was not. Through our parallel study design, the risk of all-cause mortality increases as severity of concomitant ILD or PH worsens. Therapies that target slowing disease progression earlier in the disease course may be beneficial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available